| Code | CSB-RA004929MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to daratumumab, targeting CD38, a type II transmembrane glycoprotein with both receptor and ectoenzyme functions. CD38 is expressed on various immune cells and catalyzes the synthesis and hydrolysis of cyclic ADP-ribose, playing crucial roles in calcium signaling, cell adhesion, and signal transduction. This protein exhibits particularly high expression on multiple myeloma cells and other hematologic malignancies, making it an important therapeutic target. CD38 is also involved in the regulation of immune responses and has been implicated in chronic lymphocytic leukemia, acute lymphoblastic leukemia, and certain solid tumors.
Daratumumab, the reference antibody, is a human IgG1κ monoclonal antibody that was the first CD38-targeted therapy approved for multiple myeloma treatment. This biosimilar provides researchers with a valuable tool for investigating CD38-mediated mechanisms, including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis induction in malignant cells. It supports studies in oncology, immunology, and hematologic disease research, enabling exploration of CD38 biology and therapeutic mechanisms.
There are currently no reviews for this product.